201 related articles for article (PubMed ID: 32352653)
21. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
Kivitz AJ; Wagner U; Dokoupilova E; Supronik J; Martin R; Talloczy Z; Richards HB; Porter B
Rheumatol Ther; 2018 Dec; 5(2):447-462. PubMed ID: 30121827
[TBL] [Abstract][Full Text] [Related]
22. Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy.
Godzenko AA; Agafonova EM; Dimitreva AE; Razumova IY; Urumova MM
Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861150
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
Kishimoto M; Taniguchi A; Fujishige A; Kaneko S; Haemmerle S; Porter BO; Kobayashi S
Mod Rheumatol; 2020 Jan; 30(1):132-140. PubMed ID: 30334633
[No Abstract] [Full Text] [Related]
24. [HLA B 27 uveitis in ankylosing spondylitis and reactive arthritis].
Dumbrăveanu L; Cuşnir V; Groppa L; Calinina L
Oftalmologia; 2010; 54(1):29-35. PubMed ID: 20540366
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis.
Yazgan S; Celik U; Işık M; Yeşil NK; Baki AE; Şahin H; Gencer E; Doğan İ
Int Ophthalmol; 2017 Feb; 37(1):139-145. PubMed ID: 27154720
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
Pavelka K; Kivitz AJ; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Wang Y; Porter BO; Stefanska A; Richards HB; Rohrer S;
ACR Open Rheumatol; 2020 Feb; 2(2):119-127. PubMed ID: 31957970
[TBL] [Abstract][Full Text] [Related]
27. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab: first global approval.
Sanford M; McKeage K
Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
[TBL] [Abstract][Full Text] [Related]
29. Profile of secukinumab in the treatment of psoriasis: current perspectives.
Roman M; Madkan VK; Chiu MW
Ther Clin Risk Manag; 2015; 11():1767-77. PubMed ID: 26664127
[TBL] [Abstract][Full Text] [Related]
30. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
[TBL] [Abstract][Full Text] [Related]
31. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Sieper J; Deodhar A; Marzo-Ortega H; Aelion JA; Blanco R; Jui-Cheng T; Andersson M; Porter B; Richards HB;
Ann Rheum Dis; 2017 Mar; 76(3):571-592. PubMed ID: 27582421
[TBL] [Abstract][Full Text] [Related]
32. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
Dick AD; Tugal-Tutkun I; Foster S; Zierhut M; Melissa Liew SH; Bezlyak V; Androudi S
Ophthalmology; 2013 Apr; 120(4):777-87. PubMed ID: 23290985
[TBL] [Abstract][Full Text] [Related]
33. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
[TBL] [Abstract][Full Text] [Related]
34. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Braun J; Baraliakos X; Listing J; Sieper J
Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
[TBL] [Abstract][Full Text] [Related]
35. Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
Sun R; Bustamante M; Gurusamy VK; Lebwohl M; Gottlieb AB; Mease PJ; Deodhar A; Bao W; Mendelson M; Porter B; Chand D; Dong V
Dermatol Ther (Heidelb); 2024 Mar; 14(3):729-743. PubMed ID: 38451423
[TBL] [Abstract][Full Text] [Related]
36. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
[TBL] [Abstract][Full Text] [Related]
37. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.
Mease PJ; Kavanaugh A; Reimold A; Tahir H; Rech J; Hall S; Geusens P; Pellet P; Delicha EM; Pricop L; Mpofu S;
ACR Open Rheumatol; 2020 Jan; 2(1):18-25. PubMed ID: 31943974
[TBL] [Abstract][Full Text] [Related]
38. Higher risk of uveitis and dactylitis and older age of onset among ankylosing spondylitis patients with HLA-B*2705 than patients with HLA-B*2704 in the Chinese population.
Qi J; Li Q; Lin Z; Liao Z; Wei Q; Cao S; Rong J; Hu Z; Yang M; Zhang Y; Lv Q; Huang J; Pan Y; Wu Y; Jin O; Li T; Gu J
Tissue Antigens; 2013 Dec; 82(6):380-6. PubMed ID: 24498994
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
[TBL] [Abstract][Full Text] [Related]
40. Secukinumab induced Behçet's syndrome: a report of two cases.
Dincses E; Yurttas B; Esatoglu SN; Melikoglu M; Hamuryudan V; Seyahi E
Oxf Med Case Reports; 2019 May; 2019(5):omz041. PubMed ID: 31198577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
